Research & Development
Heron Therapeutics APONVIE receives US FDA approval for PONV in adults
19 September 2022 -

Heron Therapeutics, Inc. (NASDAQ: HRTX), a US-based commercial-stage biotechnology company, announced on Friday that it has received approval from the United States Food and Drug Administration (FDA) for its APONVIE (aprepitant) injectable emulsion, for intravenous use in the prevention of postoperative nausea and vomiting (PONV) in adults.

The product, claimed to be the first and only IV formulation of aprepitant for PONV prevention, is administered through a single 30-second IV injection that reaches drug levels associated with less than or equal to 97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for around 48 hours. It is offered in a single-dose vial that delivers the complete 32mg dose approved for PONV.

Barry Quart, Pharm.D., Heron chairman and chief executive officer, said, 'With the approval of APONVIE our acute care portfolio now addresses the two most common concerns of patients and clinicians after surgery, postoperative pain and postoperative nausea and vomiting. This marks an important milestone for our expanding acute care portfolio and is a testament to our ongoing commitment to developing innovative solutions to help improve the overall patient experience after surgery. With approximately 36 million procedures in the US each year in patients with high to moderate risk for PONV, the approval of APONVIE provides an easy to use, highly effective option for these patients that fits seamlessly into our acute care franchise.'



Related Headlines